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850Objective: After univentricular Fontan conversion, systemic venous pressure serves as the sole driving force for
transpulmonary blood flow. Consequently, systemic venous return is markedly altered and ventricular filling is
subnormal. The mechanisms and time course of systemic adaptation to Fontan conversion are incompletely un-
derstood. We hypothesized that acute elevation in systemic venous pressure induces an adaptive response similar
to conversion to a univentricular Fontan circulation.
Methods:Adjustable vessel occluders were placed around the superior and inferior vena cavae in juvenile sheep.
After 1-week recovery, occluders were tightened to acutely increase and maintain systemic venous pressure at 15
mm Hg (n ¼ 6), simulating 1-stage Fontan conversion. Control animals (n ¼ 4) received identical surgery, but
venous pressure was not manipulated.
Results: Cardiac index decreased significantly (3.9  1.0 mL/min/m2 to 2.7  0.7 mL/min/m2, P< .001) and
then normalized to control at 2 weeks. Circulating blood volume increased (100  9.4 mL/kg vs 85.5  8.4
mL/kg, P ¼ .034) as a persistent response. Cardiac reserve improved and was not different from control by
week 3. Resting heart rate decreased in both groups. Oxygen extraction (arteriovenous oxygen difference) and
neurohormonal mediators increased transiently and then normalized by week 2.
Conclusions: Adaptation to global elevation in systemic venous pressure to Fontan levels is complete within 2
weeks. Increased blood volume and reduced heart rate are persistent responses. Increased oxygen extraction and
neurohormonal up-regulation are temporary responses that normalize with recovery of cardiac output. With im-
proved physiologic understanding of systemic adaptation to Fontan conversion, approaches to single-ventricle
palliation can be more objectively assessed and optimized. (J Thorac Cardiovasc Surg 2010;140:850-6)Supplemental material is available online.
Fontan repair of a functional single ventricle is performed us-
ing a staged surgical approach. This strategy, which has
evolved on a clinical basis, remains problematic.1 Although
stage II volume unloading of the single ventricle provides
early partial ventricular volume reduction and improvement
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The Journal of Thoracic and Cardiovascular Surgwith improved late ventricular function or exercise perfor-
mance.2 Thus, themajority of the benefit of interim staging ex-
ists early, likely from take-downof the systemic-to-pulmonary
arterial shunt. Furthermore, evidence increasingly suggests
that early Fontan conversion is associated with improved
long-term ventricular function, incidence of normal sinus
rhythm, and freedom from atrioventricular valve insufficiency
(all presumably secondary to decreased interval of ventricular
volume overload).1,2 This is consistent with current trends
toward earlier repair. Because Fontan conversion at an early
age may improve long-term outcome by limiting the period
of ventricular volume overload and hypoxemia associated
with an interim-staged approach, the best long-term status
may derive from avoidance of ventricular volume load or
use of a shunt altogether, thus, early primary repair.3
In select patients, Fontan conversion can be performed in
1 stage with excellent results.4 This has fallen out of favor
because of improved safety margin and early outcomes
achieved with interim palliation (earlier take-down of the
systemic arterial shunt, with partial improvement in hypox-
emia, partial reduction in ventricular volume load, and par-
tial return to series circulation). Perhaps more important,
however, staged conversion imposes less physiologic stress
on the systemic venous, capillary, and interstitial circulation
with partial (superior vena cava [SVC]), rather than globalery c October 2010
Abbreviations and Acronyms
Aortasat ¼ aortic oxygen saturation
IVC ¼ inferior vena cava
IVCsat ¼ inferior vena cava oxygen saturation
RAAS ¼ renin-angiotensin-aldosterone system
SVC ¼ superior vena cava
SVCsat ¼ superior vena cava oxygen saturation
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nous pressure. Because decisions to perform Fontan staging
have historically revolved around downstream pulmonary
vascular resistance (ironically exacerbated by shunt physiol-
ogy), the upstream systemic aspects of Fontan conversion
have been largely overlooked.
Coupled with these questions, evolving circulatory sup-
port concepts are making compression of staging and earlier
conversion to Fontan an increasingly realistic consider-
ation.5 Temporary mechanical cavopulmonary assist can
support the time-limited process of systemic and interstitial
adaptation to global increase in systemic venous pressure.
Although it may improve the margin of safety for direct Fon-
tan conversion, the duration required to bridge to unsup-
ported Fontan is not known. The goal of this study is to
define the physiologic events and timeframe to Fontan
steady state, with respect to the systemic circulation.
MATERIALS AND METHODS
Animal Model
Juvenile sheep (3 months old, n¼ 10) underwent right thoracotomy. The
right and left azygous veins were ligated. Transthoracic pressure monitoring
lines were placed in the pulmonary artery, aorta, SVC, IVC, right atrium,
and left atrium. An ultrasonic flowprobe (Transonic, Ithaca, NY) was placed
around the ascending aorta. Percutaneous adjustable vessel occluders (Fine
Science Tools, Foster City, Calif) were placed around the juxtacardiac IVC
and SVC (Figure 1). During 1-week recovery, normal hemodynamics were
maintained. Transthoracic pressures (zeroed at olecranon; head neutral) and
cardiac output were monitored daily. Animals were allowed unrestricted ac-
cess to food and water.
Systemic Venous Pressure Elevation
On experimental day 0 (day of intervention), baseline hemodynamics
were measured. In 6 animals, vena caval occluders were incrementally tight-
ened over 15 to 20 minutes to achieve SVC and IVC pressures of 14 to
15 mm Hg. This was selected as the upper limit of ‘‘normal’’ systemic ve-
nous pressure in patients with Fontan, a range that allows documentation of
hemodynamic response with few clinical symptoms. Aortic, SVC, and IVC
samples were drawn before and after the pressure increase for oxygen satu-
ration (OSM3 hemoximeter, Radiometer,Westlake, Ohio). Venous pressure
was monitored twice daily for 5 days to ensure consistency; beyond day 5,
occluder adjustment was seldom required. Control animals (n ¼ 4) were
identically monitored, with no manipulation of venous pressure.
Assessment of Cardiac Reserve
Dobutamine infusion (10 mg/kg/min, 20 minutes) was used to quantify
cardiac reserve at 5 time points: study 1, experimental day1 (1 day beforeThe Journal of Thoracic and Cavenous restriction) for baseline; study 2, experimental day 3; study 3, day 7;
study 4, day 14; and study 5, day 21. Hemodynamic variables were recorded
at 5-minute intervals, including 5 minutes after termination. Aortic, SVC,
and IVC samples were drawn before and after dobutamine infusion for ox-
ygen saturation.
Cerebral Oximetry
Cerebral oximetry was monitored using near-infrared spectroscopy
(Somanetics Inc, Troy, Mich) in 4 experimental animals at the time of ve-
nous pressure increase and during dobutamine challenges.
Circulating Blood Volume
Blood volume was determined at the time of surgery, the day after ve-
nous pressure intervention, and before all dobutamine studies using dilution
technique (Evan’s Blue dye).6 Absorbance of plasma drawn from the SVC
was measured using a standard spectrophotometric curve. Total blood vol-
ume (milliliters/kilogram) was calculated from plasma volume and hemat-
ocrit (blood volume ¼ plasma volume/(1  hematocrit)). Animals were
weighed the same day of blood volume determination.
Neurohormonal Markers
Serum and plasma were collected for antidiuretic hormone, aldosterone,
angiotensin II, epinephrine, norepinephrine, and brain natriuretic peptide
determination before administering Evan’s Blue dye or dobutamine on stud-
ies 1 to 5, as well as the day after venous pressure increase. Samples were
frozen at80C and batch analyzed (Anilytics Inc, Gaithersburg, Md).
Statistical Analysis
Results are reported as mean  standard deviation. Data were analyzed
by pairwise comparison within and between control and experimental
groups, including time factor for all time points, by 2-way analysis of var-
iance with correction for repeated measures using Student Newman–Keuls
post hoc test. Cerebral oxygen saturation data were analyzed by regression.
Statistical analysis was performed with SigmaStat software (Systat, Rich-
mond, Calif).
The experimental protocol was approved by the Animal Care and Use
Committee of the Indiana University School of Medicine. Animals received
humane care in accordance with the ‘‘Guide for the Care and Use of Labo-
ratory Animals’’ prepared by the Institute of Laboratory Animal Resources
and published by the National Institutes of Health (publication 86-23,
revised 1996).RESULTS
Hemodynamic Response to Acute Elevation in
Systemic Venous Pressure
The 3-fold elevation in systemic venous pressure was sur-
prisingly well tolerated; only 1 animal became unsteady and
needed to lie down. In all instances, venous pressure of at
least 12 mm Hg was achieved at the initial intervention;
goal pressure was achieved in most animals. Pressure adjust-
ments (4–5 mmHg) were common in the afternoon of exper-
imental day 0, but were subsequently few and minor
(<2–3 mm Hg). SVC and IVC pressures were maintained
at 15 mm Hg over the duration of the study (Figure 2). Car-
diac index decreased significantly in the experimental group,
but normalized by day 14 to control (Figure 3). Systemic ar-
terial blood pressure was not affected by increased systemic
venous pressure, although heart rate did decrease signifi-
cantly in control animals during the last 2 weeks of the studyrdiovascular Surgery c Volume 140, Number 4 851
FIGURE 1. Experimental model. PSVC, Pressure superior vena cava; PIVC,
pressure inferior vena cava; PRA, pressure right atrium; PLA, pressure left
atrium; PPA, pressure pulmonary artery.
FIGURE 2. Systemic venous pressure: increased and maintained at goal
range (14–15 mm Hg) in SVC (A) and IVC (B) distributions days 1 to
20. Adjusted measurement indicates adjustment required in vena caval re-
striction to maintain measured systemic venous pressure within goal param-
eters after the initial value at that time interval had been determined.
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pressure in experimental animals reached significance on ex-
perimental days 2, 4, 5, 7, 8, 10, and 16. Pulmonary vascular
resistance increased in the experimental group in concert
with decreased right ventricular preload and cardiac index.
Cardiac Reserve
A significant heart rate response occurred in both groups
to dobutamine infusion, with no between-group difference
(Figure E1, A, B). In the experimental group, cardiac index
was significantly decreased in comparison with control at
baseline for studies 2 and 3, and after dobutamine for studies
2, 3, and 4 (Figure E1, C, D). Controls had a significant in-
crease in cardiac index from baseline for all 5 studies, but ex-
perimental animals did not significantly augment cardiac
index in response to dobutamine during studies 2 and 3.
Blood Volume
Blood volume increased in the experimental group and
was significantly higher than baseline on days 3, 7, 14,
and 20. Blood volume was significantly higher than control
on days 14 and 20 (Figure 4).
Neurohormonal Markers
Aldosterone and angiotensin II were significantly ele-
vated in the experimental group early after the increase in
systemic venous pressure, but normalized to control after
week 1 (Figure 5). Antidiuretic hormone also increased852 The Journal of Thoracic and Cardiovascular Surgearly, but was not significant (Table E2). No statistical dif-
ference was seen in brain natriuretic peptide, epinephrine,
and norepinephrine levels in experimental versus control
groups (Table E2).
Blood Gases and Cerebral Oximetry
Aortic oxygen saturation (Aortasat), SVC oxygen satura-
tion (SVCsat), and IVC oxygen saturation (IVCsat) data are
presented in Table E1. SVCsat was significantly decreased
at baseline for studies 2 and 3, and increased significantly
in response to dobutamine during studies 2, 3, and 4
(Figure E2, B). IVCsat was significantly decreased at base-
line for all studies and did not increase in response to dobut-
amine (Figure E2, D). There was no change in SVCsat or
IVCsat in controls (Figure E2, A, C). Cerebral saturation in-
creased in response to dobutamine in all cases (Figure E2,
E). Oxygen extraction (Aortasat – SVCsat or IVCsat) was
calculated. Significant group differences in SVC oxygen
extraction were seen on days 1, 2, 3, 7 (Figure E3, A). Groupery c October 2010
FIGURE 3. Cardiac index: significant reduction after intervention, with
normalization by day 14. *Significant difference between experimental
and control groups (P  .05).
FIGURE5. Serum aldosterone (A) and angiotensin II (B). *Significant dif-
ference (P  .05) from control.
Myers et al Congenital Heart Disease
C
H
Ddifferences in IVC oxygen extraction were seen on days 2
and 3 (Figure E3, B). Cerebral oximetry correlated with
SVC and IVC oxygen saturation both before and after the in-
crease in venous pressure and dobutamine studies. A total of
48 measurements were taken each for cerebral oximetry,
SVCsat and IVCsat using 4 experimental animals. Cerebral
oximetry values correlated significantly with SVCsat
(R ¼ 0.789, P< .001) and IVCsat (R ¼ 0.525, P< .001)
(Figure E4).
Necropsy
Left and right azygous vein ligation was confirmed in all
cases. There was no evidence of venous thrombus. Small
right pleural effusion (<100 mL) was present in most ani-
mals. One animal exhibited significant ascites (6 liters).
Comment
With increasing numbers of Fontan survivors reaching
adulthood, the long-term sequelae of single-ventricle Fontan
palliation is now recognized as an emerging public healthFIGURE 4. Blood volume. *Significant difference (P .05) from control.
#Significant difference (P  .05) from baseline.
The Journal of Thoracic and Caconcern.7 Regression from compensated to uncompensated
systemic venous hypertension is integral to the pathogenesis
of both early and late Fontan failure.8,9 Although long
proposed, medical therapies aimed at controlling fluid
retention, decreasing pulmonary resistance, and optimizing
ventricular function via increased contractility or afterload
reduction remain limited and suboptimal.
Systemic compensatory mechanisms undoubtedly play an
important role in Fontan homeostasis, including hemody-
namic, interstitial, oncotic, neuroendocrine, and renin-
angiotensin axis regulation. These mechanisms are poorly
understood. Venous hypertension, construed as an immuta-
ble consequence of Fontan physiology, has been clinically
approached as a problem to minimize or avoid. An impedi-
ment to objective resolution of this problem is that chronic
models of Fontan do not exist; mechanisms underlying Fon-
tan homeostasis and failure are not well defined. Complete10
and partial right-sided heart bypass11 in the context of me-
chanical support of cavopulmonary flow have been reported,
but none have achieved chronic survival, limiting the abilityrdiovascular Surgery c Volume 140, Number 4 853
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tive period.
Hemodynamic Response to Restricted Systemic
Venous Return
In this study, systemic venous pressure was acutely and
globally (both SVC and IVC distributions) elevated in
awake, conscious animals as a systemic physiologic mimic
of 1-stage Fontan conversion. This differs from clinical
staged Fontan conversion where pressure elevation in the
SVC and IVC distributions are punctual events separated
in time and occur in a setting of general anesthesia and car-
diopulmonary bypass-associated myocardial dysfunction
and capillary leak. Without superimposed capillary leak
and third spacing, the findings in this study suggest that
1-stage Fontan conversion may be readily achievable once
perioperative fluid shifting is complete and lung parenchy-
mal function is optimized. Normalization of cardiac reserve
may reflect a recovered ability to fill the right ventricle as the
result of increased preload, although this is not borne out by
measured left atrial pressure values. This demonstrates adap-
tation beyond resting cardiac index, for which increased
blood volume presumably plays a key role.
Heart Rate Response to Restricted Systemic Venous
Return
Heart rate disturbances and autonomic dysfunction are
well documented late after Fontan.12 Sinus node dysfunction
and bradycardia have been attributed to surgical injury near
the atrial pacemaker complex. In this study, there was no dif-
ference in heart rate between control and experimental ani-
mals at any time point. There was an overall trend toward
decreasing heart rate for both groups that reached signifi-
cance after week 2 for control animals. The cause of the heart
rate decrease is unclear, but it may be attributed to acclima-
tization to the testing procedures or postsurgical recovery.
Both groups retained equivalent ability to increase heart
rate in response to dobutamine, with no difference in basal
epinephrine and norepinephrine levels, indicating no endog-
enous catecholamine response to systemic venous restric-
tion. Counter to expectations that an increase in heart rate
will occur in response to reduced cardiac output after Fon-
tan, a decrease in heart rate may represent a natural compen-
satory mechanism aimed to prolong diastolic filling time. It
may also be secondary to increased cerebral venous pres-
sure. This has clinical implications for low resting heart
rate in patients undergoing the Fontan procedure; recent
studies have, in fact, independently associated low resting
heart rate with higher functional status.13,14
Cerebral Oximetric Response to Restricted Systemic
Venous Return
Despite the inability to increase cardiac index in response
to dobutamine, cerebral oximetry values and SVCsat854 The Journal of Thoracic and Cardiovascular Surgincreased during dobutamine infusion. IVCsat remained un-
changed or decreased. This indicates that blood flow is pref-
erentially shifted to the cerebral circulation in response to
dobutamine. SVCsat and IVCsat both correlated well with ce-
rebral oximetry, but oximetry values more closely approxi-
mated the change in SVCsat in response to dobutamine
when initial saturation was subnormal. In agreement with
clinical findings, cerebral oximetry strongly predicts
SVCsat.
15
Neuroendocrine Response to Restricted Systemic
Venous Return
The neurohormonal response to intervention includes the
following: (1) up-regulation of the renin-angiotensin-
aldosterone system (RAAS) by increase in angiotensin II
and aldosterone, with subsequent normalization beyond
1 week (Figure 5); (2) increased blood volume in the period
that RAAS is up-regulated, and which persists after angio-
tensin II and aldosterone have normalized. Therefore, adap-
tive mechanisms beyond RAAS up-regulation must remain
in play to maintain increased blood volume. There is likely
a shift in RAAS over time because its role in chronic Fontan
physiology seems to differ from that in the immediate post-
operative period.
In animal models, acute and chronic restriction of the IVC
alone has been used to induce low cardiac output and an anti-
natriuretic response.16-18 In these studies, diminished
cardiac output, ascites formation, increased total peripheral
resistance, decreased sodium and potassium excretion,
decreased glomerular filtration rate, and antinatriuresis are
secondary to decrease in cardiac output and sodium
retention mediated by RAAS. RAAS response has been
examined clinically early and late after Fontan. RAAS
response is up-regulated early after Fontan and bidirectional
Glenn cavopulmonary anastomosis19 and has been impli-
cated in the development of effusions, but trials using
angiotensin-converting enzyme inhibitors have mixed re-
sults. Chronically after Fontan, adrenergic tone and RAAS
are up-regulated,20 although in one study blood volume
was not significantly different from biventricular circula-
tions.21 A randomized controlled trial of angiotensin-
converting enzyme inhibitor administration late after Fontan
demonstrated no improvement in exercise performance.22
Is Staged Palliation the Best Long-Term Strategy?
Interim staged palliation may represent a trade-off be-
tween improved early outcomes, but worsened long-term
status. Basal health of the pulmonary vascular bed, in part
a reflection of previous staging procedures in which a shunt
was used,23 is the critical inflection point on which ultimate
Fontan upstream systemic venous pressure and downstream
ventricular filling depend. As a result, a palliative strategy
designed to preserve ventricular function and basal pulmo-
nary vascular resistance is of prime importance. Becauseery c October 2010
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Da strategy of shunt palliation and intermediate staging may
induce irreversible alterations in the myocardium before
volume unloading, it can be argued that this may worsen
candidacy for Fontan conversion and long-term functional
status.1,2 Consideration of approaches that may reduce, or
eliminate, use of a shunt or interval staging is timely and
clinically relevant, and merits investigation.
The Case for Direct Fontan Repair
The best strategy may be primary Fontan repair with no
staging at all: Precisely how this can be accomplished is
a provocative and complex matter. Minimizing or avoiding
Fontan staging (combined stage 2 and 3, or stage 1, 2, and 3
Fontan conversion) by performing primary Fontan repair,
with temporary mechanical cavopulmonary assist, has com-
pelling theoretic advantages.3,10 The interval of ventricular
volume overload and hypoxemia is reduced or eliminated,
which may reduce the incidence of ventricular
hypertrophy and diastolic dysfunction. Also, minimization
of hypoxemia and early return to normoxia would reduce
the stimulus for pulmonary hypertension and pathologic
pulmonary vascular remodeling. Finally, the interstage
interval and a second or third open procedure, all
significant risk factors for mortality, would be obviated by
direct conversion to Fontan.
Duration of Support as Bridge to Fontan
Adaptation to Fontan venous pressure is complete within 2
weeks; this is a reasonable duration within which percutane-
ous mechanical circulatory support can be applied. During
support, 2-ventricle physiologic conditions are replicated,
with no unsafe upper limit to oxygenation, a more stable
series circulation, and no ventricular volume overload. An ob-
vious concern is risk of elevated pulmonary resistance in new-
borns. However, in normal human neonates, pulmonary
resistance decreases rapidly to within 10% of adult values
within the first 2 to 3 days of life.24,25 Experimental data
that we have generated in newborn lambs with mechanically
assisted cavopulmonary blood flow also support this, with
normalization of pulmonary resistance in response to
mechanical cavopulmonary assist within 8 hours.3 Physio-
logic details remain to be determined, but, under ideal physi-
ologic conditions, neonates are clearly capable of maintaining
low pulmonary resistance. Adjuncts, such as selective pulmo-
nary vasodilators, may facilitate transition from supported to
unsupported neonatal Fontan repair of single ventricles.
Study Limitations
This is not a true model of a Fontan circulation, but rather
a model of systemic venous hypertension in a biventricular
circulation. Although the model produces chronic elevation
in systemic venous pressure, it differs in important ways
from a Fontan procedure. The right ventricle is maintained
in the circulation, and the downstream resistor to venous re-The Journal of Thoracic and Caturn is a fixed anatomic obstruction rather than physiologic
pulmonary resistance. Blood is still pumped to the lungs
by the right ventricle, rather than being driven passively
by systemic venous pressure. The interactions of respiration,
gravity, IVC, and hepatic venous and transpulmonary blood
flow, all of which are important in the Fontan circulation, are
not accounted for. Also, the effects of pulmonary resistance
on systemic impedance when added in series to the systemic
circulation are not examined or accounted for.CONCLUSIONS
Absent an existing chronic model of Fontan, the model
provides a reasonable estimate of the systemic transitional
events that occur in 1-stage Fontan conversion and may
serve for study of systemic Fontan pathophysiology. In
this analysis, selective restriction of SVC and IVC return
to model intermediate staging was not performed; studies
of this nature must account for venous collateral shunting
to the opposing unrestricted venous territory. Because the
study was performed in juvenile animals, firm conclusions
regarding neonatal adaptation to elevated systemic venous
pressure cannot be drawn. The findings in this study eluci-
date the mechanisms of global adaptation to Fontan-level
venous pressure and define the time course for this transition
to stably occur. This information may be useful to guide
optimization strategies for Fontan palliation.References
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FIGURE E1. Heart rate in control (A) and experimental (B) groups, and cardiac index in control (C) and experimental (D) groups at baseline and after
20-minute dobutamine infusion. Study 1: 1 day before intervention. Study 2: 3 days postintervention. Study 3: 7 days postintervention. Study 4: 14 days
postintervention. Study 5: 21 days postintervention. *Significant difference (P  .05) from control. #Significant difference (P  .05) from study 1.
ySignificant difference (P  .05) from baseline.
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FIGURE E2. Blood oxygen saturation in SVC in control (A) and experimental (B) animals and IVC in control (C) and experimental (D) animals at baseline
after 20-minute dobutamine infusion. E, Represents near-infrared spectroscopy measurements in experimental animals (n ¼ 4) at baseline after 20-minute
dobutamine infusion. Study 1: 1 day before intervention. Study 2: 3 days postintervention. Study 3: 7 days postintervention. Study 4: 14 days postintervention.
Study 5: 21 days postintervention. *Significant difference (P  .05) from control. #Significant difference (P  .05) from study 1 values. ySignificant differ-
ence (P  .05) from baseline. SVC, Superior vena cava; IVC, inferior vena cava; NIRS, near-infrared spectroscopy.
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FIGURE E3. Oxygen extraction in the SVC (A) and IVC (B) versus time.
*Significant difference (P  .05) from control. #Significant difference
(P  .05) from baseline. SVC, Superior vena cava; IVC, inferior vena cava.
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FIGURE E4. Correlation between cerebral near-infrared spectroscopy
measurements and SVC (A) and IVC (B) blood oxygen saturation in exper-
imental animals (n ¼ 4). P< .001.
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TABLE E1. Hemodynamic and blood gas data
Parameter Baseline (day 0 preintervention) Day 1 Day 3
III Group Value II Value I II Value I II
Heart rate (beats/min) .048 Control 151  11.6 .391 145  18 .865 .868 138  39 .641 .274
Experimental 139  8.6 148  31 .075 122  31 .987
Systolic blood pressure
(mm Hg)
.869 Control 98  5 .510 103  3 .988 .053 100  7 .992 .130
Experimental 95  10 94  10 .996 93  9 .996
Diastolic blood pressure
(mm Hg)
.982 Control 76  6 79  4 NS 75  4 NS
Experimental 76  7 73  12 70  9
Superior vena cava pressure
(mm Hg)
<.001 Control 5  2 .496 4  2 .899 <.001 5  2 1.000 <.001
Experimental 4  2 14  1 <.001 15  1 <.001
Inferior vena cava pressure
(mm Hg)
<.001 Control 5  2 .339 3  2 .199 <.001 5  3 .999 <.001
Experimental 3  2 15  1 <.001 15  1 <.001
Cardiac index (cardiac output/
weight, expressed in units
L/min/m2)
<.001 Control 4.2  0.9 .547 4.5  0.9 1.000 .001 4.4  1.1 1.000 .002
Experimental 3.9  1.0 2.7  0.7 <.001 2.7  0.4 <.001
Mean pulmonary arterial
pressure (mm Hg)
.960 Control 17  2 .156 16  1 .935 .351 17  1 .970 .139
Experimental 15  2 15  2 .999 15  2 .995
Right atrial pressure (mm Hg) .169 Control 3  2 1.3  2.3 NS 2  2.6 NS
Experimental 0.8  1.8 0.8  1.9 0.4  4
Left atrial pressure (mm Hg) .119 Control 2.3  2.1 2.5  1.9 NS 1.8  2.2 NS
Experimental 1.2  2.2 0.8  3 0.7  2.7
Pulmonary vascular
resistance, calculated as
(PPAPLA) 3 80/(cardiac
output/weight), expressed
as 103 dynes/cm5/kg
.001 Control 9.4  2.6 .827 8.6  1.9 .999 .021 9.9  4.0 1.000 .058
Experimental 9.9  3.2 14.8  4.9 .027 14.8  4.7 .025
Arterial oxygen saturation (%) .255 Control 89.5  4.7 90.1  2.4 91  4.4
Experimental 89.7  5.2 90.3  2.0 89.8  2.6
SVC oxygen saturation (%) .001 Control 52.5  2.8 .651 54.4  4.0 .984 <.001 57.1  3.7 .839 <.001
Experimental 54.1  7.5 40.1  7.5 <.001 39.6  8.7 <.001
IVC oxygen saturation (%) <.001 Control 56.7  7.1 .678 55.7  5.0 .947 .287 57.2  7.7 .873 .003
Experimental 58.7  4.6 50.6  7.2 .018 40.5  12.4 <.001
Plasma volume (mL/kg) .059 Control 85.8  12 .876 87.3  14 .945 .444 87.8  13 .972 .058
Experimental 84.8  8.7 92.3  13 .059 100.7  7.3 .002
Day 7 Day 14 Day 21
Parameter Group Value I II Value I II Value I II
Heart rate (beats/min) Control 128  21 .458 .827 111  11 .028 .89 103  23 .006 .297
Experimental 124  15 .972 113  16 .908 119  20 .967
Systolic blood pressure
(mm Hg)
Control 94  5 .657 .762 98  7 .898 .844 99  9 .949 .303
Experimental 95  8 1.000 97  6 .954 94  4 .997
Diastolic blood pressure
(mm Hg)
Control 74  3 NS 76  5 NS 75  6 NS
Experimental 73  8 75  6 71  5
Superior vena cava pressure
(mm Hg)
Control 5  1 .999 <.001 5  2 .880 <.001 3  2 .316 <.001
Experimental 14  1 <.001 14  1 <.001 14  2 <.001
Inferior vena cava pressure
(mm Hg)
Control 5  1 .993 <.001 7  4 .955 <.001 5  4 .998 <.001
Experimental 14  1 <.001 15  1 <.001 15  1 <.001
Cardiac index (cardiac output/
weight, expressed in units
L/min/m2)
Control 4.2  0.7 1.000 .038 4.2  0.9 .999 .074 4.0  0.6 .775 .789
Experimental 3.2  0.7 .129 3.3  0.9 .302 3.9  0.7 .977
Mean pulmonary arterial
pressure (mm Hg)
Control 20  4 .718 .023 17  1 .965 .124 17  1 .990 .194
Experimental 16  3 .944 15  2 .995 15  2 .981
Right atrial pressure (mm Hg) Control 4.7  3.2 NS 2.3  3.5 NS 2.7  2.3 NS
Experimental 0.2  1.8 0.2  2.5 1.4  1.7
(Continued)
Myers et al Congenital Heart Disease
The Journal of Thoracic and Cardiovascular Surgery c Volume 140, Number 4 856.e5
C
H
D
TABLE E1. Continued
Day 7 Day 14 Day 21
Parameter Group Value I II Value I II Value I II
Left atrial pressure (mm Hg) Control 3.5  2.6 NS 3  2.8 NS 3.3  3.2 NS
Experimental 0  1.3 0  0.6 2.5  2.6
Pulmonary vascular
resistance, calculated as
(PPAPLA) 3 80/(cardiac
output/weight), expressed as
103 dynes/cm5/kg
Control 10.7  4.1 .999 .134 9.3  3.4 1.000 .159 9.5  2.5 1.000 .895
Experimental 14.5  5.1 .036 12.8  3.8 .308 9.2  3.1 .941
Arterial oxygen saturation (%) Control 91.4  3.9 92.8  1.3 91.2  0.6
Experimental 90  2.9 90.6  2.5 88.1  2.7
SVC oxygen saturation (%) Control 56.7  1.3 .009 .001 53.7  3.4 .985 .165 59.5  0.9 .487 .057
Experimental 44.2  6.9 .835 48.7  5.1 .240 52.7  7.4 .516
IVC oxygen saturation (%) Control 55.1  7.4 .985 .436 55.1  6.2 .957 .312 56.5  1.2 .817 .206
Experimental 51.3  7.1 .027 50.2  5.4 .018 51.2  5.0 .030
Plasma volume (mL/kg) Control 86.8  4.7 .841 .072 87.9  9.1 .992 .020 85.5  8.4 .950 .034
Experimental 98.8  7 .002 104  8.5 <.001 100  9.4 .002
SVC, Superior vena cava; IVC, inferior vena cava; SD, standard deviation. Values expressed as mean  SD. Control group includes n ¼ 4 measurements; experimental group
includes n ¼ 6 measurements for all variables and time points. Columns headed by I are P values for within-group comparisons with baseline. Columns headed by II are P values
for between-group comparisons. The column headed by III shows P values for 2-way analysis of variance group effect for time. Significant P values are in bold.
TABLE E2. Serum neurohormonal markers
Group
Study 1
(Day1)
Postintervention
(Day 0)
Study 2
(Day 3)
Study 3
(Day 7)
Study 4
(Day 14)
Study 5
(Day 21)
ADH (pg/mL) Control 1.15  1.11 2.11  0.9 1.64  1.13 2  0.83 2.72  1.07 2.85  0.64
Experimental 2.6  1.03 21.14  38.64 3.82  2.31 4.39  1.82 3.1  2.31 3.43  2.09
Aldosterone (pg/mL) Control 58.2  18.59 41.68  42.43 59.44  41.88 17.82  27.55 16.62  22.09 47.78  56.15
Experimental 106.7  116.9 252.3  230.4 284.7  230.1 58.6  86.8 107.2  203.8 32.5  32.5
Angiotensin II (pg/mL) Control 506.5  306 601  206.8 518.6  174.1 424.1  108.4 474.3  230.9 550.1  160.7
Experimental 1610.1  701.3 3261.2  2394.3 4576.8  3894.5 2840.6  2528.7 1745.4  1337.4 1759.3  1109.5
BNP (ng/mL) Control 0.25  0.03 0.26  0.06 0.31  0.08 0.32  0.12 0.38  0.12 0.33  0.1
Experimental 0.3  0.07 0.22  0.03 0.21  0.02 0.27  0.08 0.27  0.05 0.28  0.03
Epinephrine (ng/mL) Control 0.09  0.05 0.05  0.05 0.07  0.05 0.04  0.03 0.09  0.09 0.07  0.09
Experimental 0.08  0.03 0.15  0.09 0.11  0.07 0.02  0.02 0.00  0.01 0.01  0.02
Norepinephrine (ng/mL) Control 0.58  0.29 0.42  0.22 0.63  0.22 0.51  0.38 0.61  0.5 0.58  0.44
Experimental 1.25  0.75 1.2  0.88 1.48  1.36 0.97  0.69 0.22  0.16 0.47  0.26
ADH, Antidiuretic hormone; BNP, brain natriuretic peptide. Values expressed as mean  SD. Control group includes n ¼ 4 measurements and experimental group includes n ¼5
measurements for all variables and time points, except angiotensin II, for which n ¼ 3 in the experimental group.
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